| |
|
|
|
|
|
 |
| |
|
´º·Î½ºÆÇ½Ã·´ NEUROSPAN SYRUP
|
|
ÀϹÝÀǾàǰ | ºñ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
622800500[A05351761]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
[ºñ±Þ¿©]
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹æÇâÀÌ ÀÖ°í ´Ü¸ÀÀ» °¡Áø ¿¬ÇÑ °¥»öÀÇ ¸¼Àº ½Ã·´Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
ÀÚ»çÆ÷Àå´ÜÀ§¿¡ µû¸§ |
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
Á¡¸·Àå¾Ö¿Í ±âħÀ» ¼ö¹ÝÇÏ´Â ±Þ¤ý¸¸¼º ±â°üÁö¿°
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¿ë¹ý¿ë¹ý.¿ë·®
´ÙÀ½ÀÇ ¿¬·É°ú üÁß¿¡ µû¶ó 1ÀÏ 3ȸ º¹¿ëÇÑ´Ù.
¿¬·É(¼¼) 1ȸ¿ë·®(1ÀÏ 3ȸ Åõ¿©)
12°³¿ù ±îÁö 1ȸ 1.1mL
1-2¼¼ 1ȸ 2.2mL
2-6¼¼ 1ȸ 3.2mL
6-12¼¼ 1ȸ 4.3mL
12¼¼ ÀÌ»ó ¹× ¼ºÀÎ 1ȸ 5.4mL
º»Á¦¸¦ º¹¿ë ÈÄ À½·ù(¹°, Á꽺, Â÷)¸¦ ¸¶½Å´Ù.
|
| ±Ý±â |
µ¿ ¼ººÐ¿¡ °ú¹ÎÁõÀÌ Àִ ȯÀÚ
|
| ½ÅÁßÅõ¿© |
ÀӺΠ¹× ¼öÀ¯ºÎÀÇ °æ¿ì ÀÇ»çÀÇ Áö½Ã°¡ ÀÖÀ» °æ¿ì¿¡¸¸ º¹¿ëÇÒ °Í
|
| ÀÌ»ó¹ÝÀÀ |
»ó´ã½Ã °¡´ÉÇÑ ÀÌ Ã·ºÎ¹®¼¸¦ ¼ÒÁöÇÒ °Í
1) °ú·®À¸·Î º¹¿ëÇÑ °æ¿ì¿¡´Â À§ÀÇ ÀÚ±ØÀ̳ª ±¸Åä ¹× ¼³»ç°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) ¼ÒÈÀå¾Ö ¹× ±¸¿ª µîÀÌ ¾ÆÁÖ µå¹°°Ô ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) ¼öÀϰ£ º¹¿ëÇÏ¿©µµ Áõ»óÀÇ °³¼±ÀÌ º¸ÀÌÁö ¾ÊÀ» °æ¿ì
|
| Off-label Usage |
[Á¶È¸]
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| ¼ººÐÄÚµå |
M086642/»çÇâÃÊÀ¯µ¿¿¢½º 15.0±×·¥ /
M100050/Çìµ¥¶óÇ︮½Ã½º¿±70%¿¡Åº¿ÃÀ¯µ¿¿¢½º 1.5±×·¥ /
|
| ´ëÇ¥ÄÚµå |
8806228005009 |
| BIT ¾àÈ¿ºÐ·ù |
ÁøÇذŴãÁ¦ & ±âħ°¨±â¾à (Cough & Cold remedies)
|
| ATC ÄÚµå |
Cough suppressants and expectorants / R05FB02
[ÄÚµåºÐ·ù»ó¼¼¼³¸í]
[ATCÄÚµå¿¹Ãø]
|
| º¹ÁöºÎºÐ·ùÄÚµå |
222 (ÁøÇذŴãÁ¦ )
|
ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä |
[ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä]
|
| Drugs By Indication |
[Àüüº¸±â]
|
| Drugs By Classification |
[Àüüº¸±â]
|
|
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Ethanol¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
ethanol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The sedative effects of ethanol are mediated through binding to GABA receptors and glycine receptors (alpha 1 and alpha 2 subunits). In its role as an anti-infective, ethanol acts as an osmolyte or dehydrating agent that disrupts the osmotic balance across cell membranes.
|
| Pharmacology |
ethanol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Alcohol produces injury to cells by dehydration and precipitation of the cytoplasm or protoplasm. This accounts for its bacteriocidal and antifungal action. When alcohol is injected in close proximity to nerve tissues, it produces neuritis and nerve degeneration (neurolysis). Ninety to 98% of ethanol that enters the body is completely oxidized. Ethanol is also used as a cosolvent to dissolve many insoluble drugs and to serve as a mild sedative in some medicinal formulations.
|
| Absorption |
ethanol¿¡ ´ëÇÑ Absorption Á¤º¸ Rapidly absorbed.
|
| Toxicity |
ethanol¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral, rat LD50: 5628 mg/kg. Symptoms and effects of overdose include nausea, vomiting, CNS depression, acute respiratory failure or death and with chronic use, severe health problems, such as liver and brain damage.
|
| Drug Interactions |
ethanol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸] ethanol¿¡ ´ëÇÑ P450 table
SUBSTRATES
CYP 2E1
acetaminophen
chlorzoxazone
**ethanol**
INHIBITORS
CYP 2E1
disulfiram
INDUCERS
CYP 2E1
**ethanol**
isoniazid
SUBSTRATES
CYP 2E1
acetaminophen
chlorzoxazone
**ethanol**
INHIBITORS
CYP 2E1
disulfiram
INDUCERS
CYP 2E1
**ethanol**
isoniazid
|
| Drug Target |
[Drug Target]
|
| Description |
ethanol¿¡ ´ëÇÑ Description Á¤º¸ A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages. [PubChem]
|
| Drug Category |
ethanol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Infective Agents, LocalCentral Nervous System DepressantsDisinfectantsSolvents
|
| Smiles String Canonical |
ethanol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCO
|
| Smiles String Isomeric |
ethanol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCO
|
| InChI Identifier |
ethanol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ Not Available
|
| Chemical IUPAC Name |
ethanol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ ethanol
|
| Drug-Induced Toxicity Related Proteins |
ETHANOL ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Proenkephalin Drug:ethanol Toxicity:ethanol narcosis. [¹Ù·Î°¡±â] Replated Protein:Insulin receptor substrate 1 Drug:Ethanol Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation. [¹Ù·Î°¡±â] Replated Protein:Phosphatidylinositol-4-phosphate 3-kinase Drug:Ethanol Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation. [¹Ù·Î°¡±â] Replated Protein:Insulin receptor substrate 2 Drug:Ethanol Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation. [¹Ù·Î°¡±â] Replated Protein:Mitogen-activated protein kinase(Erk2) Drug:Ethanol Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation. [¹Ù·Î°¡±â] Replated Protein:Mitogen-activated protein kinase Drug:Ethanol Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-09-30
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|